Company intelligence / Profile preview

DiamiR

Monmouth Junction, New Jersey, United States

Ownership: Public · DIMR
Development stage: Other

Overview

DiamiR’s brain-enriched microRNA biomarker assays in plasma differentiate mild cognitive impairment from controls with >0.90 accuracy, predict cognitive decline years before clinical diagnosis, and can distinguish several neurodegenerative diseases. Data are published, but system-wide clinical validation and regulatory approval is in progress.

Therapeutic areas: Neurology
Modalities: Diagnostic (microRNA biomarker assay)
Industry: Molecular Diagnostics

Partnerships

Leading academic centersdisease foundationsbiopharma partners (explicit names not provided in public sources)

Beyond the preview

Go deeper on DiamiR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiamiR.

Explore the full profile